Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is anticipated to release its earnings data before the market opens on ...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Ratings reports. Two analysts ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other ...

Compass Therapeutics Inc (NASDAQ:CMPX) is a biopharmaceutical company that makes antibody-based therapies for several diseases. The stock is up significantly so far in 2025 due to it reporting ...

BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics ...

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of ...